Workflow
医学检验及服务
icon
Search documents
金域医学: 广州金域医学检验集团股份有限公司第四届监事会第六次会议决议公告
Zheng Quan Zhi Xing· 2025-08-22 16:28
证券代码:603882 证券简称:金域医学 公告编号:2025-035 一、监事会会议召开情况 广州金域医学检验集团股份有限公司(以下简称"公司")第四届监事会第 六次会议于 2025 年 8 月 22 日在公司会议室以现场的方式召开,会议通知已于 应出席监事 3 名,实际出席监事 3 名。本次会议的通知和召开程序符合《中华人 民共和国公司法》、 《广州金域医学检验集团股份有限公司章程》的相关规定,本 次会议及其决议合法有效。 二、监事会会议审议情况 出席本次会议的全体监事对本次会议的议案进行了认真审议,并以记名投票 表决方式通过以下决议: (一)审议通过《广州金域医学检验集团股份有限公司 2025 年半年度报告 全文及摘要》 经审议,监事会认为,2025 年半年度报告的编制和审议程序符合法律、法 规、公司章程和公司内部管理制度的各项规定;报告的内容和格式符合中国证监 会和上海证券交易所的各项规定,所包含的信息能真实、准确、完整地反映出公 司报告期内的经营管理和财务状况等事项;未发现参与报告编制和审议的人员有 违反保密规定的行为。具体内容详见同日于上海证券交易所网站 (www.sse.com.cn)及公司指定 ...
金域医学: 广州金域医学检验集团股份有限公司股东国创开元股权投资基金(有限合伙)减持股份计划公告
Zheng Quan Zhi Xing· 2025-07-08 11:18
Group 1 - The major shareholder, Guochuang Kaiyuan Equity Investment Fund (Limited Partnership), plans to reduce its holdings in Guangzhou Kingmed Diagnostics Group Co., Ltd. by up to 4,632,582 shares, which represents a maximum of 1.00% of the company's total share capital [4][5][6] - As of the announcement date, Guochuang Kaiyuan holds 30,880,905 shares, accounting for 6.67% of the company's total share capital, all of which were acquired prior to the company's initial public offering (IPO) [4][5] - The reduction is driven by the shareholder's personal funding needs and will be executed through centralized bidding from July 30, 2025, to October 29, 2025 [5][6] Group 2 - Guochuang Kaiyuan is not a controlling shareholder or actual controller of the company, and this reduction plan is not expected to significantly impact the company's governance structure or ongoing operations [6][7] - The shareholder has committed to comply with relevant laws and regulations regarding the reduction of shares and will disclose the progress of the reduction plan as required [6][7]
金域医学: 广州金域医学检验集团股份有限公司关于股东部分股份质押展期的公告
Zheng Quan Zhi Xing· 2025-06-23 16:31
Summary of Key Points Core Viewpoint - The announcement details the extension of share pledges by the major shareholder of Guangzhou Kingmed Diagnostics Group Co., Ltd., indicating a significant portion of shares are pledged, which may impact the company's financial stability and investor confidence. Group 1: Share Pledge Details - The shareholder, Shengyutang, directly holds 21,000,000 shares, accounting for 4.53% of the total share capital of the company [1] - The current extension involves 8,580,000 shares, which represents 40.86% of Shengyutang's directly held shares and 1.85% of the company's total share capital [1] - After the extension, the total pledged shares by the controlling shareholder and related parties amount to 31,580,000 shares, which is 19.14% of their total holdings and 6.82% of the company's total share capital [1][6] Group 2: Pledge Status and Implications - As of the announcement date, the controlling shareholder, Liang Yaoming, and his associates have a cumulative pledge of shares, which includes Shengyutang and other investment partnerships [2] - The total number of pledged shares is 164,983,621, representing 35.61% of the total share capital, with 31,580,000 shares newly pledged [6] - The company will closely monitor the developments regarding these pledges and will disclose relevant information in accordance with regulations [6][7]
金域医学(603882):医保控费政策+应收减值影响短期业绩 看好ICL持续复苏和AI赋能
Xin Lang Cai Jing· 2025-05-08 12:33
Core Viewpoint - The company reported a significant decline in revenue and net profit for 2024, with ongoing challenges in the market impacting performance, but there are signs of potential recovery in the testing business and advancements in digital transformation [1][3][4]. Financial Performance - In 2024, the company achieved operating revenue of 7.19 billion, a year-on-year decrease of 15.81%, and a net profit attributable to shareholders of -0.38 billion, a decline of 159.26% [1] - For Q1 2025, the company reported operating revenue of 1.47 billion, down 20.35%, and a net profit of -0.03 billion, a decrease of 49.09% [1] - The fourth quarter of 2024 saw operating revenue of 1.57 billion, a decline of 29.57%, and a net profit of -0.48 billion, a drop of 805.23% [1] Cost Structure - In 2024, the sales expense ratio was 12.94%, an increase of 1.06 percentage points; the management expense ratio was 8.32%, a slight decrease of 0.05 percentage points; the R&D expense ratio was 5.57%, up by 0.10 percentage points; and the financial expense ratio was -0.04%, down by 0.03 percentage points [2] - The gross profit margin for 2024 was 33.15%, a decrease of 3.33 percentage points, primarily due to reduced revenue scale and increased fixed cost amortization [2] - The net profit margin for 2024 was -5.77%, a decline of 13.23 percentage points [2] Market and Business Outlook - The testing business is expected to gradually recover, with the company focusing on product innovation and maintaining a leading market share despite competitive pressures [3] - In 2024, the company saw a 2.94% increase in specimen testing volume, with significant revenue growth in specialized products such as tumor screening (69.7% increase) and blood cancer RNA-seq (170% increase) [3] - The company is enhancing its digital transformation efforts, utilizing AI and big data to improve laboratory efficiency by 50-90% and expanding its service platform to over 570,000 downstream clients [4] Profit Forecast and Investment Recommendation - The company adjusted its profit forecast, expecting revenues of 7.50 billion, 8.22 billion, and 9.02 billion for 2025-2027, with net profits of 0.35 billion, 0.64 billion, and 0.70 billion respectively [4] - The company is positioned to benefit from industry growth and improved laboratory profitability, maintaining a "buy" rating [4]